Biotech firm Odyssey targets $810 million in valuation in US IPO

• Odyssey plans to raise up to $238.3 million through the sale of 13.2 million shares in its IPO
• The company will list on the Nasdaq Capital Market under the ticker symbol 'ODTX'
• April 2025 was the busiest month for U.S. IPO filings in over four years, signaling a potential pickup in market activity

Summary

Key Development:

Odyssey Therapeutics, a biopharmaceutical company, announced plans for a U.S. initial public offering targeting a valuation of up to $809.9 million. The company aims to raise up to $238.3 million by offering 13.2 million shares.

Listing Details:

• Exchange: Nasdaq Capital Market
• Ticker symbol: ODTX
• Lead underwriters: J.P. Morgan, TD Cowen, and Cantor

Market Context:

The IPO represents part of a broader revival in the U.S. IPO market. According to Renaissance Capital, April marked the busiest month for new IPO filings in over four years, signaling a potential reopening of the market after an extended period of limited activity. This uptick suggests improving conditions for companies seeking to go public in the coming months.

Industry Significance:

The biotech sector continues to access public markets despite previous challenging conditions for IPOs. Odyssey's offering reflects renewed investor appetite for biopharmaceutical investments and improved market sentiment.

Timeline:

The announcement was made on May 4, with listing expected to follow standard IPO procedures in the near term.

The successful completion of this offering would provide Odyssey with substantial capital to advance its therapeutic programs while serving as a barometer for other biotech companies considering public listings. The broader IPO market revival could encourage additional companies across sectors to pursue listings after years of subdued activity.